Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) therapy for unresectable hepatocellular carcinoma (uHCC): CheckMate 9DW expanded analyses.

Bibliographic Details
Title:	Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) therapy for unresectable hepatocellular carcinoma (uHCC): CheckMate 9DW expanded analyses.
Authors:	Kudo, Masatoshi, Yau, Thomas, Decaens, Thomas, Sangro, Bruno, Qin, Shukui, Da Fonseca, Leonardo, Karachiwala, Hatim, Park, Joong-Won, Gane, Edward, Pinter, Matthias, Tai, David, Santoro, Armando, Pizarro, Gonzalo, Chiu, Chang-Fang, Schenker, Michael, He, Aiwu Ruth, Hu, Nan, Jimenez Exposito, Maria Jesus, Stromko, Caitlyn, Galle, Peter Robert
Source:	Journal of Clinical Oncology; 2025 Supplement 4, Vol. 43, p520-520, 132p
Database:	Supplemental Index

More Details
ISSN:	0732183X
DOI:	10.1200/JCO.2025.43.4_suppl.520
Published in:	Journal of Clinical Oncology
Language:	English